Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.
Autor:
Peixin Chen, Chunyan Wu, Minlin Jiang, Yi Xu, Liping Zhang, Jun Zhu, Chenglong Sun, Yayi He, Jia Yu, Caicun Zhou, Shengyu Wu, Hao Wang, Qiyu Fang, Hui Sun, Wencheng Zhao, Zixuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related exp
Autor:
Sharon Ng, Meenal Sinha, Rahul Aggarwal, Terence W. Friedlander, Christopher Nguyen, Li Zhang, Sumit K. Subudhi, Brandon Chen, E Liu, Alexander Cheung, Padmanee Sharma, Kate Allaire, James P. Allison, Lawrence Fong, Matthew H. Spitzer, Eric J. Small, Jaqueline Marquez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
BackgroundSipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after
Autor:
Stefan Traint, Sebastian Bauer, Thomas Brodowicz, Gerwin Heller, Katharina Feldmann, Julia Furtner, Gabriele Amann, Rainer Hamacher, Teresa Hatziioannou, Iris M. Noebauer-Huhmann, Leonhard Müllauer, Wolfgang Lamm, Angelika M. Starzer, Erwin Tomasich, Hans-Ulrich Schildhaus, Anna S. Berghoff, Matthias Preusser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSome sarcomas respond to immune checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA methylation profiles in relation to immunological parameters and response to anti-programmed cell death 1 (anti-PD-1) immune
Autor:
Magali Svrcek, Quentin Letourneur, Toky Ratovomanana, Adrien Buisson, Anna Pellat, François Paye, Lucile Armenoult, Christelle De La Fouchardiere, Thierry André, Romain Cohen, Alex Duval, Mira Ayadi, Matthieu Sarabi, Vincent Jonchère, Pierre Meeus, Raphael Colle
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Metastatic colorectal cancers (mCRC) harboring microsatellite instability (MSI) are sensitive to immune checkpoint inhibitors (ICIs), but the mechanisms of resistance to ICIs remain unclear. Dissociated responses in patients with ICI-treated cancer s